Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Receptor mediated glycotargeting

M S Wadhwa1, K G Rice

  • 1College of Pharmacy, Ohio State University, Columbus 43210, USA.

Journal of Drug Targeting
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA Technology to Regenerate and Repair Alveolar Bone Defects.

Journal of dental research·2024
Same author

Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver.

Gene therapy·2015
Same author

The uptake mechanism of PEGylated DNA polyplexes by the liver influences gene expression.

Gene therapy·2014
Same author

Attachment in adolescence: A narrative and meta-analytic review.

Journal of youth and adolescence·2013
Same author

High-affinity PEGylated polyacridine peptide polyplexes mediate potent in vivo gene expression.

Gene therapy·2012
Same author

Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.

Gene therapy·2010
Same journal

A Novel Te-Ethosomes-loaded Thermosensitive Gel for Enhanced Transdermal Delivery and Melasma Therapy.

Journal of drug targeting·2026
Same journal

Galactosylated chitosan-functionalized liposome for targeted delivery of <i>Coreopsis tinctoria</i> flavonoids: Protective effect in acute liver injury.

Journal of drug targeting·2026
Same journal

Tubulin as a well-established yet underexploited target: new opportunities for drugs repurposing?

Journal of drug targeting·2026
Same journal

Physcion-loaded, folic acid-conjugated DSPE-PEG liposomes for targeted therapy of ulcerative colitis.

Journal of drug targeting·2026
Same journal

Enzyme-responsive 2-dimensional nanomaterials for targeted breast cancer treatment.

Journal of drug targeting·2026
Same journal

Integrating antibody-drug conjugates, multispecific antibodies, targeted protein degradation and nanomedicine in precision oncology.

Journal of drug targeting·2026
See all related articles

Glycotargeting uses carbohydrate-carrying molecules to target specific cells via mammalian lectins. Discovering new lectins will accelerate the development of novel glycotargeting agents for disease treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Glycotargeting utilizes carrier molecules with carbohydrates for recognition and internalization by cell surface mammalian lectins.
  • Various glycotargeting vehicles are created by attaching saccharides to proteins, polymers, and other molecules.
  • These carriers are crucial in antiviral therapy, immunoactivation, enzyme replacement therapy, and gene therapy.

Purpose of the Study:

  • To review and compare different types of glycotargeting agents.
  • To examine the mammalian lectins successfully targeted for disease treatment.
  • To highlight the importance of carbohydrate-protein interactions in glycotargeting.

Main Methods:

  • Literature review of glycotargeting strategies.

Related Experiment Videos

  • Analysis of glycotargeting vehicles and their applications.
  • Comparison of targeted mammalian lectins in disease models and human studies.

    • Main Results:

    • Diverse glycotargeting vehicles have been developed using carbohydrate-protein interactions.
    • Successful targeting of specific mammalian lectins has been achieved for therapeutic applications.
    • The review provides a comparative overview of existing glycotargeting agents and their efficacy.

    Conclusions:

    • The development of glycotargeting agents is based on the interaction between carbohydrates and proteins.
    • Identifying novel mammalian lectins that internalize ligands will drive innovation in glycotargeting.
    • Future advancements in glycotargeting hold significant promise for treating various diseases.